$628 Million is the total value of Ikarian Capital, LLC's 122 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CYCC | Exit | CYCLACEL PHARMACEUTICALS INC | $0 | – | -275,000 | -100.0% | -0.00% | – |
| GOSS | Exit | GOSSAMER BIO INC | $0 | – | -6,100 | -100.0% | -0.00% | – |
| Exit | ROCKET PHARMACEUTICALS INC*w exp 09/02/202 | $0 | – | -367,112 | -100.0% | -0.01% | – | |
| FNCH | Exit | FINCH THERAPEUTICS GROUP INC | $0 | – | -237,553 | -100.0% | -0.02% | – |
| STSA | Exit | SATSUMA PHARMACEUTICALS INC | $0 | – | -136,059 | -100.0% | -0.02% | – |
| SPPI | Exit | SPECTRUM PHARMACEUTICALS INC | $0 | – | -176,980 | -100.0% | -0.03% | – |
| GNFT | Exit | GENFIT S Aads | $0 | – | -32,786 | -100.0% | -0.03% | – |
| Exit | BELLICUM PHARMACEUTICALS INC | $0 | – | -448,101 | -100.0% | -0.03% | – | |
| ARKK | Exit | ARK ETF TRinnovation etf | $0 | – | -4,519 | -100.0% | -0.04% | – |
| BIIB | Exit | BIOGEN INC | $0 | – | -962 | -100.0% | -0.06% | – |
| Exit | AMYLYX PHARMACEUTICALS INC | $0 | – | -10,000 | -100.0% | -0.07% | – | |
| PTCT | Exit | PTC THERAPEUTICS INCcall | $0 | – | -9,800 | -100.0% | -0.11% | – |
| VKTX | Exit | VIKING THERAPEUTICS INC | $0 | – | -43,156 | -100.0% | -0.16% | – |
| SAGE | Exit | SAGE THERAPEUTICS INC | $0 | – | -17,805 | -100.0% | -0.17% | – |
| Exit | ACHIEVE LIFE SCIENCES INC | $0 | – | -174,714 | -100.0% | -0.22% | – | |
| IVA | Exit | INVENTIVA SAads | $0 | – | -292,599 | -100.0% | -0.23% | – |
| DCTH | Exit | DELCATH SYS INC | $0 | – | -360,569 | -100.0% | -0.24% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -60,000 | -100.0% | -0.26% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -8,324 | -100.0% | -0.26% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -33,100 | -100.0% | -0.28% | – |
| BTAI | Exit | BIOXCEL THERAPEUTICS INCcall | $0 | – | -71,200 | -100.0% | -0.30% | – |
| ARKG | Exit | ARK ETF TRgenomic rev etf | $0 | – | -46,462 | -100.0% | -0.32% | – |
| MORF | Exit | MORPHIC HLDG INC | $0 | – | -45,873 | -100.0% | -0.39% | – |
| MGNX | Exit | MACROGENICS INC | $0 | – | -250,000 | -100.0% | -0.41% | – |
| AKRO | Exit | AKERO THERAPEUTICS INC | $0 | – | -50,000 | -100.0% | -0.43% | – |
| CYTK | Exit | CYTOKINETICS INC | $0 | – | -55,666 | -100.0% | -0.44% | – |
| Exit | VENTYX BIOSCIENCES INC | $0 | – | -65,000 | -100.0% | -0.49% | – | |
| BTAI | Exit | BIOXCEL THERAPEUTICS INC | $0 | – | -133,014 | -100.0% | -0.56% | – |
| ALT | Exit | ALTIMMUNE INC | $0 | – | -677,300 | -100.0% | -0.65% | – |
| XLV | Exit | SELECT SECTOR SPDR TRsbi healthcare | $0 | – | -27,469 | -100.0% | -0.81% | – |
| ALT | Exit | ALTIMMUNE INCcall | $0 | – | -898,600 | -100.0% | -0.86% | – |
| CLDX | Exit | CELLDEX THERAPEUTICS INC NEW | $0 | – | -106,057 | -100.0% | -0.87% | – |
| AVTE | Exit | AEROVATE THERAPEUTICS INC | $0 | – | -195,146 | -100.0% | -0.89% | – |
| CLDX | Exit | CELLDEX THERAPEUTICS INC NEWput | $0 | – | -110,000 | -100.0% | -0.90% | – |
| BCYC | Exit | BICYCLE THERAPEUTICS PLCcall | $0 | – | -200,000 | -100.0% | -0.96% | – |
| Exit | AMYLYX PHARMACEUTICALS INCcall | $0 | – | -150,000 | -100.0% | -1.00% | – | |
| ALT | Exit | ALTIMMUNE INCput | $0 | – | -1,077,200 | -100.0% | -1.03% | – |
| ACRS | Exit | ACLARIS THERAPEUTICS INCcall | $0 | – | -589,300 | -100.0% | -1.08% | – |
| BMRN | Exit | BIOMARIN PHARMACEUTICAL INC | $0 | – | -50,000 | -100.0% | -1.10% | – |
| ISEE | Exit | IVERIC BIO INC | $0 | – | -213,521 | -100.0% | -1.18% | – |
| BLU | Exit | BELLUS HEALTH INC NEW | $0 | – | -885,334 | -100.0% | -1.45% | – |
| XBI | Exit | SPDR SER TRput | $0 | – | -100,000 | -100.0% | -1.73% | – |
| MORF | Exit | MORPHIC HLDG INCcall | $0 | – | -213,400 | -100.0% | -1.82% | – |
| AXSM | Exit | AXSOME THERAPEUTICS INCcall | $0 | – | -150,000 | -100.0% | -2.10% | – |
| AXSM | Exit | AXSOME THERAPEUTICS INCput | $0 | – | -150,000 | -100.0% | -2.10% | – |
| IMVT | Exit | IMMUNOVANT INC | $0 | – | -774,398 | -100.0% | -2.72% | – |
| RXDX | Exit | PROMETHEUS BIOSCIENCES INC | $0 | – | -125,926 | -100.0% | -3.07% | – |
| ITCI | Exit | INTRA-CELLULAR THERAPIES INCcall | $0 | – | -380,000 | -100.0% | -4.67% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 15 | Q2 2023 | 1.5% |
| OCULAR THERAPEUTIX INC | 15 | Q3 2023 | 1.4% |
| SAREPTA THERAPEUTICS INC | 14 | Q3 2023 | 6.4% |
| X4 PHARMACEUTICALS INC - PIPE | 14 | Q2 2023 | 1.4% |
| PROTARA THERAPEUTICS INC | 14 | Q3 2023 | 1.2% |
| SPDR SER TR | 13 | Q3 2023 | 9.0% |
| VAXCYTE INC | 13 | Q3 2023 | 2.9% |
| TRACON PHARMACEUTICALS INC | 13 | Q3 2023 | 1.4% |
| MILESTONE PHARMACEUTICALS IN | 13 | Q3 2023 | 1.7% |
| BELLUS HEALTH INC NEW | 13 | Q1 2023 | 1.8% |
View Ikarian Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. | February 14, 2023 | 460,416 | 1.3% |
| X4 Pharmaceuticals, Inc | February 14, 2023 | 349,133 | 0.3% |
| aTYR PHARMA INC | February 14, 2022 | 35,048 | 0.1% |
| Cyclacel Pharmaceuticals, Inc. | February 14, 2022 | 99,422 | 1.0% |
| KalVista Pharmaceuticals, Inc. | February 14, 2022 | 36,576 | 0.2% |
| Lyra Therapeutics, Inc. | February 14, 2022 | 394,536 | 3.0% |
| Odonate Therapeutics, Inc. | February 14, 2022 | 1,340,631 | 3.5% |
| Protara Therapeutics, Inc. | February 14, 2022 | 279,256 | 2.5% |
| Science 37 Holdings, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| scPharmaceuticals Inc. | February 14, 2022 | 901,362 | 3.3% |
View Ikarian Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-05-17 |
| 13F-HR | 2024-05-15 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
View Ikarian Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.